Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells
Fundamental & Clinical Pharmacology · 2025-10 · 39 (5)
DOI: 10.1111/fcp.70044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 10.08.2025. Verfasst von Jiantao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Lung Neoplasms, Ovarian Neoplasms, Drug Resistance, Neoplasm, Cisplatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Barncancerfonden.
Abstract (Originalsprache)
Background
Cisplatin and its derivatives remain a cornerstone in the treatment of solid malignancies. Resistance is a major factor limiting their clinical utility.
Objectives
In the present study, we set out to interrogate therapeutic approaches to target cisplatin‐resistant cancer cells. We focused on therapies exploiting metabolic pathways that are altered in drug‐resistant cells. We sought to find an existing therapy that has monotherapy efficacy against cisplatin‐resistant cancer cells that can also re‐sensitize to cisplatin.
Methods
We used lung and ovarian cancer cell lines with acquired resistance to cisplatin together with drug sensitivity assays, conducted both with monotherapies and cisplatin combinations.
Results
We show that cancer cell lines with acquired resistance to cisplatin have altered levels of enzymes involved in glutamine metabolism, which can result in differential sensitivity to targeted agents. We show that expression of one of these enzymes—the glutamate‐cystine antiporter SLC7A11, up‐regulated 6‐fold in a cisplatin‐resistant lung cancer cell line—has potential prognostic significance in lung cancer but not ovarian cancer. After identifying a common dependency of cisplatin‐resistant cancer cells upon extracellular glutamine, we then evaluate the utility of the long‐standing anti‐leukemic therapy asparaginase (ASNase)—which possesses both asparaginase and glutaminase activity—as a potential approach. We show ASNase preferentially inhibits the proliferation of cisplatin‐resistant cancer cells and can potentially re‐sensitize these cells to cisplatin.
Conclusions
Our results underpin the prevalence of altered metabolism in cisplatin‐resistant cells and highlight the potential utility of re‐purposing ASNase to target these cells, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China.
- Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark.
- Science for Life Laboratory (SciLifeLab), Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
ORCID-Profile: Robert Strauss, Sean G Rudd
Förderung
- Vetenskapsrådet
- Cancerfonden
- Barncancerfonden
- Åke Wiberg Stiftelse
- Danish Cancer Society
- Fabrikant Chas. Otzen's Fond
- Købmand Niels Erik Munk Pedersen Fonden
- West China Hospital, Sichuan University
Zitieren
APA
Wang, J., Pouryaghoub, N., Strauss, R., Bartek, J., Zhang, S. M., & Rudd, S. G. (2025). Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells. Fundamental & Clinical Pharmacology, 39(5). https://doi.org/10.1111/fcp.70044
Vancouver
Wang J, Pouryaghoub N, Strauss R, Bartek J, Zhang SM, Rudd SG. Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells. Fundamental & Clinical Pharmacology. 2025;39(5). doi:10.1111/fcp.70044
BibTeX
@article{Wang2025,
author = {Wang, Jiantao and Pouryaghoub, Nasim and Strauss, Robert and Bartek, Jiri and Zhang, Si Min and Rudd, Sean G},
title = {Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
volume = {39},
number = {5},
doi = {10.1111/fcp.70044}
}
EUVIMED